Update on Hepatitis C Virus and HIV Coinfection

被引：0

作者：

Gemtessa, Tilahun Amdissa ^{[1
]}

Chirch, Lisa M. ^{[1
]}

机构：

[1] Univ Connecticut, Ctr Hlth, Div Infect Dis, 263 Farmington Ave, Farmington, CT 06030 USA

来源：

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY | 2013年 / 1卷 / 02期

关键词：

Hepatitis C; HCV; HIV; Coinfection; Antiretroviral therapy; ART; Drug interaction;

D O I：

10.14218/JCTH.2013.00018

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Chronic hepatitis C virus (HCV) infection has historically been difficult to treat in the HIV-infected population, owing to generally poor responses to interferon-based therapies. The recent rapid development of directly acting antiviral agents (DAAs) against HCV has the potential to revolutionize treatment of this infection in the HIV population by improving tolerability and outcome, and, ultimately, reducing the significant burden of liver-related morbidity and mortality in this population. Clinical trials to address the safety and efficacy of novel DAAs in the HCV/HIV coinfected population are ongoing, and show much promise. The rapidity of current drug discovery in the field of HCV is both impressive and daunting for clinicians who will have to master these drugs. Going forward, the inclusion of individuals from this large and growing patient population in clinical trials will be of paramount importance. (C) 2013 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.

引用

页码：109 / 115

页数：7

共 48 条

[1]

El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Et al., CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, 355, pp. 2283-2296, (2006)

[2]

Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

[3]

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Et al., Effect of early versus deferred antiretroviral therapy for HIV on survival, N Engl J Med, 360, pp. 1815-1826, (2009)

[4]

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ., The prevalence of hepatitis C virus infection in the United States, 1999 through 2002, Ann Intern Med, 144, pp. 705-714, (2006)

[5]

Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Et al., Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol, 9, pp. 524-530, (2011)

[6]

Koziel MJ, Peters MG., Viral hepatitis in HIV infection, N Engl J Med, 356, pp. 1445-1454, (2007)

[7]

Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS., The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users, J Acquir Immune Defic Syndr, 33, pp. 356-364, (2003)

[8]

Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Et al., Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965, MMWR Recomm Rep, 61, pp. 1-32, (2012)

[9]

Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002–2009, MMWR Morb Mortal Wkly Rep, 60, pp. 537-541, (2011)

[10]

Thomson EC, Smith JA, Klenerman P., The natural history of early hepatitis C virus evolution

← 1 2 3 4 5 →